Hospital
Spring View Hospital LLC
Spring View Hospital LLC was paid $23.35M by Medicaid between Jan 2018 and Dec 2024, across 171 billing codes. Its largest line is 99284, emergency room visit (serious) — 25% of everything it billed.
33Billing provider infoSPRING VIEW HOSPITAL LLC
LEBANON, KY 40033
LEBANON, KY 40033
33aNPI1780746420assigned 12/15/2006
33bProvider typeRural Acute Care Hospital
28Total paid$23.35M
24GClaims424,793
24DCodes billed171
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Rural Acute Care Hospital providers in Kentucky
Rank by total paid#6 of 10
Median peer was paid$23.35M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 71,806 | $4.54M | |
| 2019 | 58,353 | $4.21M | |
| 2020 | 56,335 | $2.78M | |
| 2021 | 59,139 | $2.83M | |
| 2022 | 64,694 | $3.22M | |
| 2023 | 62,714 | $3.12M | |
| 2024incomplete | 51,752 | $2.66M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 19,224 | 15,966 | $5.91M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 20,753 | 17,577 | $3.82M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 6,520 | 4,933 | $2.57M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.5% | 2,115 | 1,767 | $1.06M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.3% | 2,854 | 2,381 | $995K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.4% | 3,872 | 2,976 | $790K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.8% | 6,691 | 5,923 | $653K |
| 71045 | Radiologic examination, chest; single view | 2.1% | 10,234 | 7,820 | $480K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.8% | 8,872 | 1,946 | $427K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 15,470 | 5,657 | $425K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 10,577 | 8,411 | $391K |
| G0378 | Hospital observation service, per hour | 1.4% | 1,615 | 730 | $331K |
159 more codes
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 688 | $304K |
| 80053 | Comprehensive metabolic panel | 1.2% | 30,892 | $274K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 32,888 | $269K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,048 | $216K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,661 | $209K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,497 | $187K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,676 | $187K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,185 | $185K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,791 | $170K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,365 | $150K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 5,682 | $147K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,483 | $144K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 250 | $141K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,236 | $130K |
| 74018 | <1% | 1,504 | $130K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 674 | $123K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,454 | $116K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,320 | $113K |
| 73630 | <1% | 2,300 | $102K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 6,559 | $99K |
| 93017 | <1% | 667 | $94K | |
| 73610 | <1% | 1,490 | $92K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,235 | $92K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,031 | $91K |
| 71250 | <1% | 445 | $77K | |
| 59025 | Fetal non-stress test | <1% | 1,013 | $70K |
| 73130 | <1% | 1,345 | $69K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,235 | $67K |
| 36415 | Collection of venous blood by venipuncture | <1% | 18,747 | $66K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 9,419 | $65K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,721 | $63K |
| 81001 | <1% | 13,553 | $63K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,985 | $60K |
| 84484 | <1% | 6,133 | $59K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,385 | $50K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 721 | $48K |
| 80061 | Lipid panel | <1% | 1,991 | $48K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,111 | $34K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,302 | $34K |
| 73560 | <1% | 727 | $33K | |
| 84703 | <1% | 4,656 | $32K | |
| 73030 | <1% | 734 | $30K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,699 | $30K |
| 72131 | <1% | 121 | $29K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 58 | $27K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 6,850 | $27K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,089 | $27K |
| 86140 | <1% | 4,166 | $27K | |
| 83735 | <1% | 4,997 | $26K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,629 | $25K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 73 | $25K |
| 87070 | <1% | 4,384 | $23K | |
| 85610 | <1% | 6,213 | $23K | |
| 85730 | <1% | 3,683 | $22K | |
| 87081 | <1% | 4,590 | $22K | |
| 73110 | <1% | 370 | $20K | |
| 87040 | <1% | 2,031 | $19K | |
| 87420 | <1% | 1,947 | $19K | |
| 97162 | <1% | 315 | $18K | |
| 87186 | <1% | 2,149 | $18K | |
| 83690 | <1% | 3,810 | $18K | |
| 84439 | <1% | 853 | $13K | |
| 85378 | <1% | 1,927 | $13K | |
| 93971 | <1% | 155 | $12K | |
| 73562 | <1% | 207 | $12K | |
| 83880 | <1% | 451 | $12K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,309 | $10K |
| 83605 | <1% | 1,487 | $10K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 523 | $10K |
| 84145 | <1% | 510 | $9K | |
| 70486 | <1% | 42 | $9K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 480 | $9K |
| 82728 | <1% | 697 | $8K | |
| 82150 | <1% | 1,738 | $7K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,434 | $7K |
| 71271 | <1% | 73 | $7K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,803 | $7K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 119 | $7K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,553 | $6K |
| 97597 | <1% | 219 | $6K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 27 | $6K |
| 73090 | <1% | 143 | $6K | |
| 96376 | <1% | 391 | $6K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,890 | $6K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,566 | $6K |
| 93225 | <1% | 32 | $5K | |
| 81003 | <1% | 1,376 | $5K | |
| 73590 | <1% | 75 | $5K | |
| 84702 | <1% | 415 | $5K | |
| 76536 | <1% | 50 | $4K | |
| 94760 | <1% | 380 | $4K | |
| 73080 | <1% | 58 | $4K | |
| 82947 | <1% | 1,215 | $3K | |
| 62323 | <1% | 17 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,568 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 126 | $3K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 144 | $3K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,365 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,084 | $3K |
| 82803 | <1% | 183 | $3K | |
| 36600 | <1% | 203 | $3K | |
| 93242 | <1% | 16 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 882 | $3K |
| 85651 | <1% | 492 | $3K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,533 | $3K |
| 12001 | <1% | 45 | $2K | |
| 72100 | <1% | 40 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 308 | $2K |
| 82607 | <1% | 168 | $2K | |
| 76000 | <1% | 34 | $2K | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 1,037 | $2K |
| 87205 | <1% | 128 | $2K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 863 | $2K |
| 86850 | <1% | 210 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 353 | $2K |
| 83615 | <1% | 357 | $1K | |
| 73502 | <1% | 61 | $1K | |
| 76642 | <1% | 13 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 789 | $1K |
| 86308 | <1% | 65 | $1K | |
| 83540 | <1% | 199 | $1K | |
| 83550 | <1% | 131 | $972.12 | |
| Q3014 | Telehealth originating site facility fee | <1% | 161 | $946.65 |
| 84436 | <1% | 77 | $878.28 | |
| 97161 | <1% | 14 | $848.02 | |
| 29125 | <1% | 14 | $777.26 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 18 | $711.04 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 99 | $708.32 |
| J3490 | Unclassified drugs | <1% | 4,574 | $600.17 |
| 74022 | <1% | 12 | $576.35 | |
| 87522 | Neg quan hep c or qual rna | <1% | 15 | $559.48 |
| 87210 | <1% | 140 | $414.61 | |
| A9270 | Non-covered item or service | <1% | 175 | $408.33 |
| 82550 | <1% | 79 | $382.52 | |
| 87220 | <1% | 130 | $360.76 | |
| 86709 | <1% | 41 | $358.96 | |
| 82140 | <1% | 27 | $342.29 | |
| 10060 | <1% | 28 | $240.93 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 128 | $211.10 |
| 87045 | <1% | 25 | $193.53 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 69 | $153.28 |
| 0011A | <1% | 13 | $144.29 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 25 | $142.35 |
| 0012A | <1% | 13 | $141.31 | |
| 87427 | <1% | 12 | $131.60 | |
| 82746 | <1% | 13 | $123.17 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 20 | $117.94 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 33 | $116.57 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 134 | $111.82 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 67 | $89.28 |
| 82272 | <1% | 19 | $83.59 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 114 | $70.46 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 14 | $59.60 |
| 82570 | <1% | 12 | $57.59 | |
| 82247 | <1% | 14 | $55.76 | |
| 86901 | <1% | 13 | $37.99 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 28 | $33.75 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 28 | $28.50 |
| 86900 | <1% | 13 | $21.77 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.